A randomized, open-label CECOG phase II study evaluating the efficacy and safety of FOLFOX6+cetuximab versus FOLFIRI plus cetuximab as first-line therapy in patients (pts) with metastatic colorectal cancer (mCRC)

被引：0
|
作者：
Ciuleanu, T. E.
Kurteva, G.
Ocvirk, J.
Beslija, S.
Koza, I.
Papamichael, D.
Vrbanec, D.
Brodowicz, T.
Scheithauer, W.
Zielinski, C. C.
机构：
[1] Inst Oncol Cluj, Cluj Napoca, Romania
[2] Sbalo Natl Oncol Ctr, Sofia, Bulgaria
[3] Inst Oncol, Ljubljana, Slovenia
[4] Inst Oncol, Sarajevo, Bosnia & Herceg
[5] Natl Canc Inst, Bratislava, Slovakia
[6] Banc Cyprus Oncol Ctr, Nicosia, Cyprus
[7] Univ Hosp Rebro, Zagreb, Croatia
[8] Med Univ Vienna, Vienna, Austria
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2008年 / 26卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
4032
引用
收藏
页数：1
相关论文
共 50 条
  • [41] Efficacy and safety of every-2-weeks cetuximab combined with FOLFOX or FOLFIRI as first-line therapy in patients with KRAS wild-type metastatic colorectal cancer (mCRC): An Asia-Pacific nonrandomized phase II study (APEC).
    Cheng, Ann-Lii
    Cornelio, Gerardo H.
    Shen, Lin
    Price, Timothy Jay
    Yang, Tsai-Shen
    Chung, Ik-Joo
    Dai, Guanghai
    Lin, Jen-Kou
    Sharma, Atul
    Yeh, Kun-Huei
    Ma, Brigette
    Zaatar, Adel
    Guan, Zhongzhen
    Masood, Nehal
    Srimuninnimit, Vichien
    Yau, Thomas Cheung
    Sarholz, Barbara
    Lim, Robert S. C.
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [42] FOLFOX4 plus cetuximab administered weekly or every second week in the first-line treatment of patients with KRAS wild-type metastatic colorectal cancer: a randomized phase II CECOG study
    Brodowicz, T.
    Ciuleanu, T. E.
    Radosavljevic, D.
    Shacham-Shmueli, E.
    Vrbanec, D.
    Plate, S.
    Mrsic-Krmpotic, Z.
    Dank, M.
    Purkalne, G.
    Messinger, D.
    Zielinski, C. C.
    ANNALS OF ONCOLOGY, 2013, 24 (07) : 1769 - 1777
  • [43] Cetuximab plus Xeliri versus cetuximab plus xelox as first-line treatment of patients with metastatic colorectal cancer (MCRC): A randomised trial of the German Aid CRC study group
    Heinernann, V
    Fischer, Von Weikersthal L.
    Vehling-Kaiser, U.
    Stauch, M.
    Oruzio, D.
    Schulze, M.
    Hass, H.
    Weiss, J.
    Dietzfelbinger, H.
    Moosmann, N.
    ANNALS OF ONCOLOGY, 2008, 19 : 13 - 13
  • [44] KRAS status and efficacy in the first-line treatment of patients with metastatic colorectal cancer (mCRC) treated with FOLFIRI with or without cetuximab: The CRYSTAL experience
    Van Cutsem, E.
    Lang, I.
    D'haens, G.
    Moiseyenko, V.
    Zaluski, J.
    Folprecht, G.
    Tejpar, S.
    Kisker, O.
    Stroh, C.
    Rougier, P.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [45] Prognostic genomic signatures in patients with RAS and BRAF wild-type (wt) metastatic colorectal cancer (mCRC) from the phase III study of first-line FOLFIRI/cetuximab versus FOLFIRI/cetuximab followed by cetuximab (Cet) alone (ERMES study).
    Normanno, Nicola
    Rachiglio, Anna Maria
    Abate, Riziero Esposito
    Orlandi, Armando
    Maiello, Evaristo
    Maglietta, Giuseppe
    Damato, Angela
    Maiello, Monica Rosaria
    Carotenuto, Marianeve
    Calegari, Maria Alessandra
    Antonuzzo, Lorenzo
    Bordonaro, Roberto
    Zampino, Maria Giulia
    Tamberi, Stefano
    Lonardi, Sara
    Avallone, Antonio
    Latiano, Tiziana Pia
    Tamburini, Emiliano
    Barone, Carlo Antonio
    Pinto, Carmine
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [46] Results of a phase II trial of cetuximab plus XELIRI as first-line therapy of patients with advanced and/or metastatic colorectal cancer
    Cartwright, T. H.
    Kuefler, P.
    Cohn, A.
    Hyman, W.
    Yoffe, M.
    Boehm, K. A.
    Ilegbodu, D.
    Asmar, L.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [47] FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (mCRC): Analysis of patients with KRAS-mutated tumors in the randomized German AIO study KRK-0306
    Stintzing, S.
    Neumann, J.
    Jung, A.
    von Weikersthal, L. Fischer
    Decker, T.
    Vehling-Kaiser, U.
    Jaeger, E.
    Heintges, T.
    Stoll, C.
    Modest, D. P.
    Kirchner, T.
    Scheithauer, W.
    Heinemann, V.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [48] Positive hyperselection of sensitizing genomic alterations (GAs) in RAS/BRAF wild-type (wt) metastatic colorectal cancer (mCRC) patients (pts) from the phase III study of first-line FOLFIRI/cetuximab versus FOLFIRI/cetuximab followed by cetuximab (Cet) alone (ERMES)
    Normanno, N.
    Rachiglio, A. M.
    Abate, R. Esposito
    Orlandi, A.
    Maiello, E.
    Maglietta, G.
    Damato, A.
    Maiello, M. R.
    Carotenuto, M.
    Calegari, M. A.
    Antonuzzo, L.
    Bordonaro, R.
    Zampino, M. G.
    Tamberi, S.
    Lonardi, S.
    Avallone, A.
    Latiano, T. P.
    Tamburini, E.
    Barone, C. A.
    Pinto, C.
    ANNALS OF ONCOLOGY, 2024, 35 : S52 - S52
  • [49] Surufatinib plus doublet (FOLFOX/FOLFIRI) or triplet (FOLFOXIRI) chemotherapy as second-line therapy in metastatic colorectal cancer (mCRC): First-stage results of a randomized, open-label phase II trial
    Lin, R.
    Li, H.
    Chen, X.
    Zheng, L.
    Hong, Y.
    Su, L.
    Li, C.
    Zheng, S.
    Su, L.
    ANNALS OF ONCOLOGY, 2023, 34 : S70 - S70
  • [50] Axitinib or Bevacizumab Plus FOLFIRI or Modified FOLFOX-6 After Failure of First-Line Therapy for Metastatic Colorectal Cancer: A Randomized Phase II Study
    Bendell, Johanna C.
    Tournigand, Christophe
    Swieboda-Sadlej, Anna
    Barone, Carlo
    Wainberg, Zev A.
    Kim, Jong Gwang
    Pericay, Carles
    Pastorelli, Davide
    Tarazi, Jamal
    Rosbrook, Brad
    Bloom, Joanna
    Ricart, Alejandro D.
    Kim, Sinil
    Sobrero, Alberto F.
    CLINICAL COLORECTAL CANCER, 2013, 12 (04) : 239 - 247
12345